Krystal Biotech Inc (KRYS) — Cash Flow-to-Debt Ratio
Krystal Biotech Inc (KRYS) has a Cash Flow-to-Debt Ratio of 0.53x as of June 2026, meaning its operating cash flow of $74.79 Million could theoretically repay 1% of its total liabilities ($141.52 Million) in one year. See Krystal Biotech Inc (KRYS) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Krystal Biotech Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Krystal Biotech Inc across 10 annual periods. For the full cash flow conversion analysis, see Krystal Biotech Inc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Krystal Biotech Inc (2016–2025)
Year-by-year debt coverage analysis for Krystal Biotech Inc. Check cash flow quality index of Krystal Biotech Inc to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 1.76x | $200.87 Million | $114.23 Million | ▲ +55.9% |
| 2024 | 1.13x | $123.42 Million | $109.46 Million | ▲ +150.4% |
| 2023 | -2.24x | $-88.80 Million | $39.71 Million | ▲ +19.5% |
| 2022 | -2.78x | $-100.57 Million | $36.22 Million | ▼ -89.5% |
| 2021 | -1.47x | $-47.94 Million | $32.72 Million | ▼ -5.4% |
| 2020 | -1.39x | $-26.08 Million | $18.76 Million | ▲ +54.6% |
| 2019 | -3.06x | $-18.71 Million | $6.11 Million | ▲ +6.3% |
| 2018 | -3.27x | $-9.45 Million | $2.89 Million | ▲ +46.2% |
| 2017 | -6.08x | $-3.89 Million | $640.00K | ▼ -777.6% |
| 2016 | -0.69x | $-1.31 Million | $1.89 Million | — |